This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Quest Diagnostics (DGX) Tops Q3 Earnings, Revenues In Line
by Zacks Equity Research
Considering hurricanes related financial impact and recently-closed acquisitions, Quest Diagnostics' (DGX) management has revised its guidance for full year 2017.
Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?
by Zacks Equity Research
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
Is Quest Diagnostics (DGX) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Why Is Quest Diagnostics (DGX) Down 3.9% Since the Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up
by Zacks Equity Research
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Quest Diagnostics (DGX) Tops Q2 Earnings, Misses on Sales
by Zacks Equity Research
Quest Diagnostics (DGX) gains in Q2 banking on the acquisition of Med Fusion and ClearPoint.
Healthcare Q2 Earnings Slated on Jul 25: HCA, UHS & More
by Zacks Equity Research
The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas
by Zacks Equity Research
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
3 Excellent Value Picks Amid Political Grind in MedTech
by Zacks Equity Research
While the revised American Health Care Act now only needs the Senate's nod, the scenario is getting increasingly challenging for the Medical Device Space.
Here's Why You Can Buy Quest Diagnostics Stock Right Now
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.
Quest Diagnostics to Buy Outreach Lab Service in Cape Cod
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.
Quest Diagnostics Enhances Blueprint for Athletes Service
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.
Why Quest Diagnostics (DGX) is a Suitable Pick for Investors
by Zacks Equity Research
Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.
Why You Should Avoid Envision Healthcare (EVHC) Stock Now
by Zacks Equity Research
Investors' pessimism about Envision Healthcare (EVHC) has stemmed from the decline in 2017 earnings guidance, following first-quarter results.
Quest Diagnostics to Buy 2 Labs, Grow in Oncology Space
by Zacks Equity Research
Quest Diagnostics (DGX) recently announced agreements to acquire two laboratory businesses in Lewisville, Texas, namely Med Fusion and Clear Point.
Quest Diagnostics (DGX) Up 1.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics Poised on Solid Q1 Results Despite Woes
by Zacks Equity Research
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Top Ranked Momentum Stocks to Buy for April 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 24th:
Quest Diagnostics (DGX) Looks Good: Stock Moves 6% Higher
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) shares rose to 6% in the last trading session.
Quest Diagnostics (DGX) Tops Q1 Earnings & Sales Estimates
by Zacks Equity Research
Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first quarter 2017 earnings report which has just released.
Should You Sell Quest Diagnostics (DGX) Before Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.